Review on Medusa^®:a polymer-based sustained release technology for protein and peptide drugs

Authors: Chan, Y-P; Meyrueix, R; Kravtzoff, R; Nicolas, F; Lundstrom, K

Source: Expert Opinion on Drug Delivery, Volume 4, Number 4, July 2007 , pp. 441-451(11)

Buy & download fulltext article:

Price: $99.00 plus tax (Refund Policy)

Abstract:

The polymer-based Medusa^® system (Flamel Technologies) has been designed for slow release of therapeutic proteins and peptides. The Medusa II consists of a poly l-glutamate backbone grafted with hydrophobic α-tocopherol molecules, creating a colloidal suspension of nanoparticles (10 - 50 nm) in water. The sustained drug release is based on reversible drug interactions with hydrophobic nanodomains within the nanoparticles. In vivo, it is suggested that the therapeutic protein is displaced by endogenous proteins present in physiological fluids, leading to a slow drug release. The peak concentration is dramatically decreased and the protein release substantially extended. The Medusa technology has been applied to subcutaneous injection for several therapeutic proteins, such as IL-2 and IFN-α_2b, in animal models (rats, dogs, monkeys) and clinical trials in renal cancer (IL-2) and hepatitis C (IFN-α_2b) patients.

Keywords: animal models; clinical trials; polymer-protein complexes; slow release

Document Type: Research article

DOI: http://dx.doi.org/10.1517/17425247.4.4.441

Affiliations: 1: Flamel Technologies, 33 Avenue du Dr Georges Lévy, 69693 Vénissieux, France +33 472 78 34 41; +33 472 78 34 24;, Email: lundstrom@flamel.com

Publication date: 2007-07-01

More about this publication?